ClinicalTrials.gg
Not yet recruitingNCT07922590Updated Nov 6, 2026

A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation

An interventional study of Text Message (to remind of Integrated Plan content) in Alcohol Use Disorder (AUD) and Suicide Ideation, sponsored by Medical University of South Carolina. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment

Updated Nov 6, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will develop and evaluate a brief, personalized, single-session telehealth intervention combined with a four-week just-in-time adaptive intervention (JITAI) delivered via text messaging for adults with alcohol use disorder (AUD) and suicidal thoughts and behaviors. The study includes qualitative interviews, pilot testing, and a 28-day micro-randomized trial (MRT). In the MRT phase, participants (N=75) will be repeatedly randomized multiple times per day to receive text messages targeting craving and suicide ideation or to receive no message. Outcomes include alcohol craving, suicide ideation, alcohol consumption, and engagement with intervention strategies

02

Conditions studied

  • Alcohol Use Disorder (AUD)
  • Suicide Ideation

Keywords

  • alcohol
  • suicidal thoughts
  • text message
03

In context

Alcoholism

1,674 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

This study's planned enrollment of 80 is close to the median of 88 across 1,428 interventional studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

Medical University of South Carolina is the lead sponsor of 874 studies on the registry; 166 are open to participants now.

Of its 131 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Meets criteria for current (past 6 months) Alcohol Use Disorder (mild, moderate, or severe)
  • Reports at least one episode of suicidal ideation in the past 6 months
  • Currently engaged in alcohol use treatment (at least monthly participation in outpatient or intensive outpatient individual or group treatment)
  • Alcohol identified as primary substance of use
  • Resides in the United States
  • Owns a personal smartphone
  • Able and willing to provide
  • Co-occurring mood disorders (excluding bipolar disorder), anxiety disorders, or other substance use disorders are permitted

Exclusion criteria

Exclusion Criteria:

  • Current suicidal or homicidal intent
  • Suicide attempt within the past 3 months
  • Psychiatric hospitalization within the past 3 months
  • Current or past psychotic disorder or bipolar disorder
  • Alcohol withdrawal requiring medical management (e.g., CIWA-Ar score > 8)
  • Inability or unwillingness to provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Single arm. Groups of people are not randomized. Each person is repeated randomized.

    Groups of people are not randomized. Each person is repeated randomized 112 times over 28 days to text message vs no text message. Within the text message condition, there is additional randomization to text message choice and text message language conditions.

    Behavioral: Text Message (to remind of Integrated Plan content)

Interventions

  • BehavioralText Message (to remind of Integrated Plan content)

    At four time points each day (112 time points across the 28-day study), each participant will be randomized to text message or no text message. Within the text message condition, there will be further randomization to Text Message Choice and Text Message Language conditions.

06

What researchers measure

Primary outcomes

  1. Integrated Plan Engagement

    Participants will complete the following yes/no EMA item four times a day: "Since the last survey, I completed a strategy from my Integrated Plan." This item, created by the study team for this study, will assess the completion of any intervention strategy from the patient's individualized Integrated Plan during the 28 day period.

    Time frame: 28-day MRT period

  2. Alcohol Craving

    Participants will complete the following EMA item (on a 0-10 Likert scale) four times a day: "Since the last survey, I thought about drinking or how good a drink would make me feel." This item, drawn from a well-established measure of alcohol craving (Penn Alcohol Craving Scale) will assess craving during the 28 day period.

    Time frame: 28-day MRT period

  3. Suicide Ideation

    Participants will complete the following EMA item (on a 0-10 Likert scale) four times a day: "Since the last survey, I thought about killing myself." This item, drawn from a well-established interview that has also been used as a self-report measure to assess varied self-injurious thoughts and behaviors (Self-Injurious Thoughts and Behaviors Interview-Revised) will assess thoughts of suicide during the 28 day period. This item has been used previously by the PI in EMA studies.

    Time frame: 28-day MRT period

Secondary outcomes

  1. Alcohol Consumption

    Participants will complete the following EMA item to assess alcohol consumption four times a day: "Since the last survey, I drank \_\_ drinks".

    Time frame: 28-day MRT period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jul 2031, 57 months later.

Of 470 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 57 months is above that.

Counting every sponsor, half of 493 studies reached it within 33 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 6, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Jul 31, 2031
CompletionEst.
Jul 31, 2031
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07922590
Responsible party
Sponsor
First posted
Nov 6, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Jul 31, 2031 (estimated)
Completion
Jul 31, 2031 (estimated)
Last update
Nov 6, 2026

Study contacts

Margaret M Baer, PhD
Contact
baerm@musc.edu
567-218-3067
Margaret M Baer, PhD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion